Rakuten Medical intends to use the capital to develop its oncology-focused PIT platform, strengthen its business and commercial functions


Image: Rakuten Medical secures $100m funding. Photo: Courtesy of 3D Animation Production Company/Pixabay.

Rakuten Medical Inc., a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy (PIT) platform, has raised approximately US $100 million on July 31, 2019, in a Series C-1 Preferred Stock financing from Rakuten, Inc., a global leader in internet services headquartered in Japan. This investment is increasing Rakuten’s equity share of Rakuten Medical to 22.6 percent.

Rakuten Medical intends to use the additional injection of capital to expand the development of the company’s oncology-focused PIT platform, strengthen its business and commercial functions, and provide resources to further identify and evaluate new investigational compounds and indications for the potential treatment of other types of cancers using PIT.

“The additional investment from Rakuten solidifies our commitment to accelerating Rakuten Medical’s business and commercial development,” said Mickey Mikitani, chairman and CEO of Rakuten Medical. “I believe we can cultivate a sustainable health care ecosystem to provide patients with safe and easy access to, and better care in, the treatment of cancer, regardless of their nationality or income. Culturally, the technology industry has revolutionized society by being bold, action-driven and innovative; and we hope to do the same at Rakuten Medical by exploring opportunities that will combine Rakuten’s technology expertise with Rakuten Medical’s first-in-class Photoimmunotherapy platform.”

Based on the additional investment, Rakuten Medical will become an equity-method affiliate of Rakuten in the third quarter of this fiscal year.

Source: Company Press Release